Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP7 | Q93009 | 14/20 | 0.50 |
| ▸ | CDC7 | O00311 | 1/20 | 0.38 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | USP47 | Q96K76 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7127591 | 0.78 | KMT2A (0.48) | LMNAMAPTNPSR1IDO1CYP2C9 | |
| SCHEMBL7062156 | 0.75 | ALDH1A1 (0.45) | CDC7DBF4LMNAMAPTNPC1 | |
| SCHEMBL9332597 | 0.74 | LMNA (0.53) | LMNAMAPTNPSR1NPC1TSHR | |
| SCHEMBL20487610 | 0.74 | USP7 (0.50) | USP7CDC7DBF4LMNAMAPT | |
| SCHEMBL9332593 | 0.73 | ALDH1A1 (0.41) | CDC7DBF4LMNAMAPTNPSR1 | |
| SCHEMBL11356302 | 0.73 | ALDH1A1 (0.48) | LMNAMAPTNPSR1CYP2C9CYP2C19 | |
| SCHEMBL281865 | 0.71 | MAPT (0.43) | MAPTNPSR1IDO1NPC1HTT | |
| SCHEMBL29912891 | 0.69 | CDC7 (0.43) | CDC7DBF4LMNAMAPTNPSR1 | |
| SCHEMBL27158947 | 0.69 | CDC7 (0.43) | CDC7DBF4LMNAMAPTNPSR1 | |
| SCHEMBL2680448 | 0.69 | USP7 (0.56) | USP7CDC7DBF4USP47 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11273154-B2 | Azole compounds as ubiquitin-specific protease USP7 inhibitors | PROGENRA, INC. (US) | 2022-03-15 | — | — | US | disclosed |
| WO-2018160944-A1 | AZOLE COMPOUNDS AS UBIQUITIN-SPECIFIC PROTEASE USP7 INHIBITORS | PROGENRA, INC. (US) | 2018-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11273154-B2 | Azole compounds as ubiquitin-specific protease USP7 inhibitors | USP7, USP1, USP2 | USP7 1/4885CDC7 113/4885DBF4 1127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.